Page 15 - Genentech News Today

Approval based on Phase III ALINA study showing Alecensa reduced the risk of disease recurrence or death by an unprecedented 76% in people with ALK-positive early-stage resected non-small cell lung...

Previously, glofitamab had received an accelerated approval for patients with relapsed or refractory diffuse large B-cell lymphoma who received 2 or more prior lines of systemic therapy.

South City is a biotech hotbed, home to multinational firms like Genentech and Amgen, but there still remain large segments of the area’s population that are less inclined to enter

With this approval, alectinib is the first anaplastic lymphoma kinase inhibitor to be approved for patients with ALK-positive, early-stage non-small cell lung cancer.

The phase 3 STARGLO study met its primary endpoint of improved overall survival, according to Columvi’s manufacturer, Genetech.

Hong Kongs R&D Receives International Recognition HKPCs

In this article, we will be taking a look at the 12 cheap foods with anti-aging properties that longevity scientists swear by.

<h4><i>Hong Kongs First High-mast Lighting Inspection and Maintenance Robot Enables Intelligent Transformation in the Infrastructure Industry</i></h4><p/>HONG KONG SAR - <a href="https://www.media-outreach.com/">Media OutReach Newswire</a> - 19 April 2024 - The Edison Awards, known as the "Oscars of Innovation", have announced the results for 2024.

Dublin, April 18, 2024 (GLOBE NEWSWIRE) -- The

The Food and Drug Administration approved Alecensa for patients with ALK-positive non-small cell lung cancer that was surgically removed.